Angle-Closure Glaucoma Clinical Trial
Official title:
The Beijing Angle Closure Progression Study (BAPS)
The Beijing angle closure progression study (BAPS) aims to explore the 5-year incidence of PACS progressing to PAC or PACG and to determine the possible risk factors of disease progression, which may provide the evidence for choosing the accurate strategies in the management of PACS.
Status | Recruiting |
Enrollment | 825 |
Est. completion date | December 31, 2030 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 75 Years |
Eligibility | Inclusion Criteria: - "Static" gonioscopy identifying 6 or more clock hours of angle circumference in which the posterior (usually pigmented) trabecular meshwork cannot be seen in both eyes with no peripheral anterior synechiae, and normal intraocular pressure (IOP), optic nerve and visual field. - Able to provide informed consent Exclusion Criteria: - Any evidence of primary angle closure (a narrow angle as defined above, but with PAS and/or IOP > 21 mmHg) or primary angle closure glaucoma (visual field defect or glaucomatous optic neuropathy). - Previous intraocular surgery or laser treatment, such as cataract surgery, laser trabeculoplasty, trabeculectomy, laser peripheral iridectomy, and laser iridoplasty - Sign of prior acute attack, such as glaucomatous fleck, keratic precipitates, or iris atrophy. - Anterior segment structural abnormalities shown by examination, such as iris or ciliary body tumor. - Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, or lung disease, or terminal cancer. - Severe eye diseases, such as cataract, macular disease, and retinal detachment. |
Country | Name | City | State |
---|---|---|---|
China | Peking University People's Hospital | Beijing | Beeijing |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the progression rate 1 | the rate of acute angle closureanterior synechiae | 6 months | |
Primary | the progression rate 2 | the proportion of eyes developing peripheral | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05163093 -
Research on the Diagnosis and Treatment of Angle Closure Glaucoma With Abnormal Lens Zonular
|
||
Completed |
NCT00762645 -
Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
|
Phase 4 |